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This article presents an update on addiction-related medical literature for the calendar years 2010 and 2011,
focusing on studies that have implications for generalist practice. We present articles pertaining to medical
comorbidities and complications, prescription drug misuse among patients with chronic pain, screening and brief
interventions (SBIs), and pharmacotherapy for addiction.
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The goal of this paper is to identify and examine import-
ant recent advances in addiction medicine in the medical
literature that have implications for the care of patients
in primary care or other generalist settings. To accom-
plish this, the authors selected articles in the field of ad-
diction medicine and summarized, critically appraised,
and examined the articles in context of their implica-
tions for generalist practice, employing methodology
used in prior updates [1-3]. During an initial review, we
identified articles through an electronic Medline search
(limited to human studies and in English) using search
terms for alcohol and other drugs of abuse from January
2010 to January 2012. From the citations, the authors se-
lected articles for more intensive review. After this initial
review, we searched for other literature in web-based or
journal resources (e.g., Alcohol, Other Drugs, and
Health: Current Evidence [www.aodhealth.org], ACP
Journal Club, and tables of contents of relevant
journals). Through a consensus process, the authors
agreed collectively on the important articles regarding
addiction medicine that have implications for practice
for generalist clinicians.
We have divided our review into four broad categories:
medical comorbidities and complications, prescription
drug misuse among patients with chronic pain,* Correspondence: drasteg1@jhmi.edu
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reproduction in any medium, provided the orscreening and brief interventions (SBIs), and pharmaco-
therapy for addiction.
Medical comorbidities and complications
Medical complications are common for patients who
consume unhealthy amounts of alcohol, those with alco-
hol dependence, and those who use illicit drugs [4-6]. In
the United States, unhealthy alcohol consumption (i.e.,
consuming quantities that place a person at risk for
medical harm) is defined as >14 standard drinks (14 g
alcohol) weekly and >4 drinks on one occasion in the
last year for men, and >7 standard drinks weekly and >3
drinks on one occasion in the last year for women and
those over 65 years of age [7]. Consumption of this
amount can impart significant harm, including cardio-
vascular, gastroenterological, and neurological morbidity.
Heavy episodic (“binge”) consumption may impart spe-
cific harms. Furthermore, when alcohol abuse and alco-
hol dependence occur, additional specific complications
can arise, including delirium tremens. Identifying and
intervening on this condition early may reduce subse-
quent complications. Medical complications from illicit
substance use can also include cardiovascular morbidity.
Are alcohol screening scores on the AUDIT-C associated
with surgical complications?
Bradley KA and colleagues [8].
This retrospective cohort study examined surgical out-
comes among male patients from the Veterans Affairsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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healthy alcohol use using the three Alcohol Use Disor-
ders Identification Test - Consumption (AUDIT-C)
questions. The outcome was any surgical complication
within 30 days post-operatively. The rate of post-
operative complications ranged from 5.6% (95% confi-
dence interval [CI], 4.8-6.6%) for patients with AUDIT-C
scores between 1 and 4, to 14% (95% CI, 8.9-21.3%)
among patients with AUDIT-C scores of 11 or 12. The
main implication of this study was that an elevated pre-
operative AUDIT-C score can help identify patients who
are at risk for postoperative complications. This finding
suggests that these patients should be aggressively coun-
seled about cutting back on alcohol use prior to elective
surgery; however, because of the observational study de-
sign, an intervention study is needed to confirm this
recommendation.Is consistent drinking associated with risk of atrial
fibrillation?
Kodama S and colleagues [9].
Although episodic alcohol consumption increases risk
for atrial fibrillation, it is not known whether consistent
alcohol consumption does. In this meta-analysis of 14
cohort and case–control studies, the pooled odds ratio
(OR) for any alcohol use and development of atrial fibril-
lation was 1.5 (95% CI, 1.31-1.74). Atrial fibrillation rela-
tive risk was 1.08 for each 10 g per day of alcohol
consumed (95% CI, 1.05-1.10). Based on this meta-
analysis, regular drinking was associated with atrial fib-
rillation in a dose–response fashion, even at alcohol
levels below current definitions of risky use—a new and
important finding.Do pattern and type of alcohol use affect risk for
myocardial infarction and coronary death?
Ruidavets JB and colleagues [10].
Previous research has found an inverse relationship
between alcohol consumption and coronary heart dis-
ease. This prospective study followed men in France and
Ireland (aged 50–59 years) for 10 years. In examining
the association between pattern and type of alcohol con-
sumption, the authors found that binge versus non-
binge drinkers had a hazard ratio (HR) for myocardial
infarction (MI) or coronary death of 1.97 (95% CI, 1.21-
3.22). Wine drinkers, as compared with drinkers of other
alcohol types, had an HR of 0.57 (95% CI, 0.38-0.85) for
MI or coronary death. The finding of an association be-
tween binge drinking and cardiovascular health suggests
that both pattern of drinking and overall consumption
contribute to cardiovascular risk. That types of alcohol
(beer and liquor) may adversely affect coronary health is
suggestive, but type of alcohol may serve as a marker forother lifestyle factors for which this observational study
could not fully control.
Are there identifiable risk factors for seizures and
delirium tremens among patients hospitalized for alcohol
withdrawal?
Eyer F and colleagues [11].
In this retrospective study of German adults hospital-
ized for alcohol detoxification, all patients were treated
with withdrawal-score–guided benzodiazepines and anti-
epileptics. Of 827 adults, 5.6% developed delirium tre-
mens (DTs), and 7.4% had seizures. Risk of DTs
increased with a past structural brain lesion (OR, 5.8;
95% CI, 2.6-12.9) and decreased with higher platelet
count (OR, 0.42 per 100,000 platelets; 95% CI, 0.26-0.69)
and serum potassium (OR, 0.33 per 1 mmol/L; 95% CI,
0.17-0.65). Risk factors for seizures also included having
a past structural brain lesion (OR, 6.0; 95% CI, 3.0-14.1).
Other risks for seizure during admission included de-
layed peak withdrawal severity (OR, 1.2 per 10 hours;
95% CI, 3.0-14.1), and seizure as a cause of admission
(OR, 2.6; 95% CI, 1.4-4.8). Only low serum potassium
was identified as a modifiable risk factor in this study, al-
though other risk factors, such as prior head trauma or
low platelets, could alert clinicians to monitor these pa-
tients more carefully.
Are beta-blockers safe in patients with chest pain and
recent cocaine use?
Rangel C and colleagues [12].
Prior physiologic studies had suggested that the use of
beta-blockers concurrently with cocaine may lead to cor-
onary vasoconstriction [13]; however, the clinical signifi-
cance of this observation has not been established.
Nevertheless, American Heart Association guidelines
have recommended against the use of beta-blockers in
patients with chest pain who have recently used cocaine
[14].This retrospective cohort study examined mortality
among patients who presented to the emergency depart-
ment with chest pain and had a urine drug test positive
for cocaine [12]. Although the admissions were consecu-
tive, urine drug tests were not performed in a systematic
fashion. Despite this limitation, the study’s findings are
important: there was no detected association between
receipt of a beta-blocker and mortality. Patients who re-
ceived a beta-blocker in the emergency department had
an HR of 0.97 (95% CI, 0.53-1.79) for mortality, and pa-
tients who were discharged on a beta-blocker had an HR
of 0.90 (95% CI, 0.47-1.71) for all-cause mortality as
compared with those not given beta-blockers. In a sec-
ondary analysis, discharge on a beta-blocker was associ-
ated with a 70% reduction in cardiovascular death (HR,
0.29; 95% CI, 0.09-0.98). This study finds no evidence of
increased harm among patients with chest pain and
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risk of cardiovascular death among cocaine users
discharged on beta-blockers. However, patients were not
systematically tested for cocaine; untested cocaine users
in the sample may have elevated the risk of adverse out-
comes within the comparison group, thereby biasing the
results towards the null. The optimal role of beta-
blockers among patients with chest pain and cocaine use
remains unclear and requires further study.
Implications for practice
Medical harm does occur with unhealthy alcohol and
illicit drug use. The relationship between alcohol use
and cardiovascular health remain an area for ongoing in-
vestigation; furthermore, best management practices for
cocaine-related chest pain should continue to be investi-
gated. Regardless, for clinicians, the association of harms
from unhealthy alcohol use and illicit drug use may en-
courage clinicians to screen and offer tailored advice to
patients at risk from these medical complications. In
particular, since alcohol is a leading cause of preventable
death and disease in the United States, clinicians should
counsel all patients that excessive consumption of
alcohol may impart significant medical and social
complications.
Prescription drug misuse among patients with chronic
pain
Broader prescribing of opioids for chronic pain has
come with substantial increases in opioid-related over-
dose fatalities and hospitalizations. Prescribers need bet-
ter tools to identify patients who are at risk for opioid
misuse and overdose, to monitor patients receiving opi-
oid pain medication, and to treat pain safely and effect-
ively in patients who have both chronic pain and
substance use disorders (SUDs).
What characteristics are associated with prescription drug
use disorders among patients treated for chronic pain?
Liebschutz JM and colleagues [15].
Liebschutz and colleagues surveyed 597 urban
primary-care clinic patients with chronic pain taking any
analgesic to identify risk factors for a lifetime prescrip-
tion drug use disorder (PDUD) as defined using Diag-
nostic and Statistical Manual of Mental Disorders, 4th
ed. (DSM IV) criteria. The prevalence of PDUD was 18%
(110 of 597 patients surveyed). Risk factors for PDUD
were as follows: time in jail (adjusted OR, 5.1; 95% CI,
2.8-9.3), greater pain-related limitations (adjusted OR,
3.8; 95% CI, 1.2-11.7), current smoking (adjusted OR,
3.6; 95% CI, 2.0-6.2), family history of substance abuse
(adjusted OR, 3.4; 95% CI, 1.9-6.0), white race (adjusted
OR 3.2; 95% CI, 1.7-6.0), male gender (adjusted OR, 1.9;
95% CI, 1.1-3.5), and post-traumatic stress disorder(adjusted OR, 1.9; 95% CI, 1.1-3.4). All patients with life-
time PDUD had at least two of these risk factors.
How best to monitor pain patients for opioid misuse?
Starrels JL and colleagues [16].
Paulozzi LJ and colleagues [17].
Tools recommended for prescribers to monitor pa-
tients for prescription opioid misuse include treatment
agreements, urine drug testing [18,19], and utilization of
prescription drug monitoring programs [20]. Starrels
and colleagues [16] conducted a systematic review of the
effectiveness of opioid treatment agreements (OTAs)
and urine drug testing (UDT) to reduce opioid misuse
among outpatients prescribed opioids for noncancer
pain. Of the 11 studies that met inclusion criteria, three
evaluated OTAs only, one evaluated UDT only, and
seven evaluated both. All studies were observational and
were rated as poor-to-fair in quality. The four studies
where there was a comparison group reported a range of
7-23% absolute-risk reduction in opioid misuse. Several
studies included multicomponent interventions that
were not representative of common clinical practice.
Poor study quality and variation in practice setting and
interventions did not permit performing a meta-analysis.
Paulozzi and colleagues [17] conducted a national
interrupted time series analysis of state prescription drug
monitoring programs (PDMPs) to determine associa-
tions between PDMPs, opioid overdose death rates, and
prescription opioid distribution rates. Between 1999 and
2005, both opioid overdose death rates and prescription
opioid distribution rates tripled. Results of the analysis
indicated that PDMPs were not a significant predictor of
opioid overdose mortality (p = 0.3) or opioid distribution
(p = 0.6). States with PDMPs had higher Schedule-III
opioid distribution, whereas states without PDMPs had
higher Schedule-II opioid distribution. In comparison
with other PDMP and non-PDMP states, three large
states with PDMPs and tamper-resistant prescription
forms (California, New York, and Texas) did have a
lower combined opioid overdose death rate (1.65 deaths
per 100, 000 person years versus 3.13 for other PDMP
states and 2.20 for non-PDMP states) and lower opioid
distribution rates (251 morphine milligram equivalents
per person per year versus 362 for other PDMP states
and 342 for non-PDMP states).
How should patients with chronic pain and a history of
substance use be treated?
Morasco BJ and colleagues [21].
A primary-care–based chronic disease management
program for chronic pain, including psychological as-
sessment, telephone support, a four-session workshop
with a psychologist, and physical therapy, can improve
function, pain, and mood [22]. Morasco and colleagues
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controlled trial to determine whether patients with an
SUD history benefited similarly from the chronic pain
disease management program. The 20% of the study
sample (72 of 362 patients) with an SUD history were
younger, less likely to be married, less physically func-
tional, more likely to be treated with opioids, and more
likely to have depression or post-traumatic stress dis-
order. At 12 months, patients with an SUD history
assigned to the intervention group had similar pain im-
provement to intervention patients with no SUD history
(adjusted OR, 1.06; 95% CI, 0.37-3.01), whereas there
was less pain improvement among patients with an SUD
history assigned to the control group compared with
non-SUD control-group patients (adjusted OR, 0.30;
95% CI, 0.11-0.82).
Implications for practice
Awareness of key characteristics, including previous in-
carceration, more severe pain-related limitations, smok-
ing, family history of substance abuse, white race, male
gender, and post-traumatic stress disorder should help
prescribers identify patients who are at higher risk for
PDUD. Opioid treatment agreements (OTAs) and urine
drug testing (UDT) are guideline-recommended tools to
reduce prescription opioid misuse, but the evidence for
their effectiveness is not strong, and understanding how
best to incorporate them into busy primary care prac-
tices requires more research. Prescription drug monitor-
ing programs (PDMPs) are another tool increasingly
available, but have yet to show an overall impact on
overdose rates. They may shift prescribing towards med-
ications that are not as closely monitored. When com-
bined with other prescription monitoring efforts,
PDMPs may have a positive impact on opioid overdose
and prescribing rates. For patients with chronic pain and
known SUD histories, more intensive and comprehen-
sive chronic pain management programs should be of-
fered to improve pain control, because with treatment as
usual, patients with a history of SUD have worse pain
control than those without.
Screening and brief interventions
The clinical procedures of screening for unhealthy alco-
hol and substance use, providing brief interventions to
reduce unhealthy substance use, and referring for tre-
atment patients in need of specialty treatment are
evidence-based practices that are being promoted by re-
search, policy, and service organizations in the United
States [23]. This cluster of clinical activities (screening,
brief intervention, and referral to treatment [SBIRT])
has been advocated to encourage screening and improve
treatment and care coordination between general and
specialty addiction services [24,25]. An emerging body ofliterature aims to facilitate SBIRT implementation [26,27].
Recent literature has examined the ability to screen for
drug use and examine the quality of screening of un-
healthy alcohol consumption in primary care settings.
Once identified through the screening process, recent
work has examined the efficacy of brief interventions for
primary care patients with heavy drinking and alcohol de-
pendence and assessed the capability of nonphysicians to
perform brief interventions.
How does a busy clinician screen for drug use?
Smith PC and colleagues [28].
Drug use, including illicit drug use and nonmedical
use of prescription medications, is a common but poten-
tially under-recognized problem among primary care pa-
tients. Smith and colleagues sought to validate a single
question screening test for drug use and drug use disor-
ders in primary care. They asked a sample of primary
care patients, “How many times in the past year have
you used an illegal drug or used a prescription medica-
tion for nonmedical reasons?” A positive response was
any affirmative answer, and this response was compared
with the presence of past 12-month documented drug
use or drug use disorder (abuse or dependence) per
DSM IV criteria [29]. The Drug Abuse Screening Test
[30] was also administered, and drug use was confirmed
through oral testing for common illicit substances. Using
these measures, the single-item question was 100% sen-
sitive (95% CI, 90.6%-100%) and 73.5% specific (95% CI,
67.7%-78.6%) for the detection of a current drug use dis-
order. The authors concluded that the single screening
question accurately identified drug use in a sample of
primary care patients, supporting its usefulness in pri-
mary care. As primary care providers increasingly are
pressed to prevent, identify, and manage risky behaviors
among their patients, the ability of a brief screening test
for drug use and drug use disorders may encourage
greater recognition—and subsequent treatment—among
their patients.
What is the quality of screening for unhealthy alcohol
consumption in clinical practice?
Bradley KA and colleagues [31].
Alcohol screening questionnaires have typically been
examined and validated in environments where the pa-
tient completes the questionnaire or an investigator,
through an interview process, administers it. Little is
known about the performance of these instruments
when implemented as part of routine clinical care. The
environment in which screening is administered and the
quality of administration may impact the performance of
the instrument. Bradley and colleagues sought to com-
pare the result of an alcohol screening questionnaire
conducted as part of routine outpatient clinical care to
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when completed in a mailed survey to identify factors
associated with discordant screening results. They exam-
ined a national sample of 6861 VA primary care outpa-
tients who completed the three Alcohol Use Disorder
Identification Test - Consumption (AUDIT-C) questions
[32,33] during a clinical visit and then, within 90 days,
received, completed, and returned the AUDIT-C as part
of a mailed survey. The investigators used multivariable
logistic regression to estimate the prevalence of discord-
ance in the different patient subgroups based on
demographic, clinical, and primary care environment
characteristics and temporal associations (i.e., the order
of the administration of the in-clinic and mailed assess-
ments). Overall, 390 of the clinical AUDIT-C screens
and 765 of the survey AUDIT-C screens were positive
(AUDIT-C score ≥5); 61% of the positive survey screens
had negative clinical screening results. Discordance was
significantly higher among African-American patients
compared to Caucasian patients, among patients who
had a positive survey screen, and those who received
care in certain VA care networks. The authors concluded
that use of validated alcohol screening questionnaires does
not by itself ensure the quality of alcohol screening, while
the results imply that screening for alcohol consumption
using the AUDIT-C may be more effective when self-
administered versus provider-administered. Perhaps im-
proved quality of provider-administered screening will
improve the quality of screening in practice, and might
have reduced the discordant clinic and survey screening
results found in this paper.
Do brief interventions work, and, if so, for whom and by
whom?
Saitz R [34].
As SBIRT is promoted in general medical environ-
ments, screening for unhealthy alcohol use is bound to
identify patients with alcohol abuse and alcohol depend-
ence. Unfortunately, while many brief intervention effi-
cacy studies have shown an effect of reducing alcohol
consumption among patients who drink at unhealthy
levels, these same studies have generally excluded pa-
tients with alcohol abuse and dependence. In real-world
settings, clinicians may identify patients with alcohol
abuse and dependence, but are brief interventions effica-
cious for these patients? Saitz performed a systematic re-
view of brief intervention trials in the literature to
examine this question in primary care settings. Of the 16
randomized controlled studies identified that compared
outcomes among adults with unhealthy alcohol use
identified by screening who received a brief intervention
in a primary care setting with those who received no
intervention, 14 excluded some or all subjects with very
heavy alcohol use or with alcohol abuse or dependencediagnoses. In the two remaining studies [35,36], brief in-
terventions among subjects with alcohol dependence
were not found to be effective at reducing alcohol sever-
ity scores or drinking. Saitz concludes that, while alcohol
screening and brief intervention have efficacy in primary
care for patients with unhealthy alcohol use, there is a
lack of evidence for efficacy among those with abuse and
dependence. This study highlights the need to develop
new approaches to help patients with heavy alcohol use,
abuse, or dependence identified in primary care practices
via alcohol screening. If screening and brief interventions
are to continue to be advocated widely in practice, inter-
ventions or referral mechanisms for patients with severe
alcohol problems should be tested and implemented.
Sullivan LE and colleagues [37].
There are a variety of provider-, system-, and patient-
level barriers to SBIRT delivery; although not exclusively,
the majority of provider-level barriers identified are from
the physician perspective. These include concerns about
lack of time and training for performing SBIRT, percep-
tion or presence of more compelling clinical issues,
underutilization or lack of awareness of effective screen-
ing and treatment strategies for alcohol and other drugs,
and concerns about patient privacy and potential
damage to the patient-provider relationship [38,39].
Additionally, providers may perceive that screening and
intervention for unhealthy alcohol use is simply ineffect-
ive, unsatisfying, uncomfortable, or not within their role
responsibilities [40]. As early as 2003, the US Institute of
Medicine recognized that “all health professionals should
be educated to deliver patient-centered care as members
of an interdisciplinary team, emphasizing evidence-based
practice, quality improvement approaches, and informat-
ics” [41]. The implementation of SBIRT is an ideal mo-
dality to make multidisciplinary approaches to the
provision of health care a reality [40]. Sullivan and
colleagues [37] performed a systematic review of the
English literature and identified 13 studies where
nonphysician practitioners performed brief interven-
tions. Seven of these studies, encompassing a total of
2633 subjects, were included in a meta-analysis. The au-
thors found that patients who received nonphysician in-
terventions consumed 1.7 fewer standard drinks per
week than control subjects (95% CI, 0.03-3.5) and con-
cluded that nonphysician brief interventions are mod-
estly effective at reducing drinking in primary care
settings. Although it is unclear whether nonphysician
interventions are as effective as those performed by
physicians, this study highlights the importance of
nonphysician providers in the identification and treat-
ment of patients with addiction in primary care. Models
of care should incorporate training and flexibility for
nonphysician providers to perform brief interventions
for unhealthy alcohol use in practice.
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Screening, brief intervention, and referral to treatment
has been widely advocated to reduce the harms associ-
ated with unhealthy alcohol consumption. These studies
indicate that screening for drug use may be possible,
that the way we screen for unhealthy alcohol consump-
tion may be important, that brief interventions for alco-
hol abuse or dependence may not be effective, and that
brief interventions can be performed by nonphysicians.
Clinicians must make careful choices regarding how to
screen, what to screen for, and what interventions are
appropriate for patients with alcohol and drug use. The
evidence base to steer these choices has yet to be
established for the gamut of alcohol and drug use disor-
ders that generalist physicians encounter in clinical
practice.
Pharmacotherapy for addiction
Pharmacotherapy for opioid dependence
For many years, methadone, an opioid agonist, was the
main pharmacologic treatment option for opioid de-
pendence, but its availability in the United States was
limited to licensed programs. The introduction of
another opioid agonist in the form of sublingual
buprenorphine, which can be prescribed in office-based
practices, has greatly expanded access to treatment for
individuals with opioid dependence. Although the effect-
iveness of buprenorphine has been demonstrated in clin-
ical trials [42] and confirmed in observational studies
[43], there are still questions about how best to deliver
this treatment and its impact on the treatment of other
conditions. The opioid antagonist naltrexone has been
available as a treatment for opioid dependence for many
years, but its use has been limited, particularly in coun-
tries where agonist treatment is available. The recent
FDA approval of an injectable extended-release formula-
tion of naltrexone offers a new pharmacologic applica-
tion of this medication.
Does adjunctive counseling improve outcomes for
outpatients receiving buprenorphine for opioid
dependence?
Weiss RD and colleagues [44].
Although office-based buprenorphine has been shown
to be an effective treatment for opioid dependence, the
impact of adjunctive counseling remains uncertain [45].
Weiss and colleagues [44] investigated this question
in a randomized controlled trial that recruited 653
prescription-opioid–dependent adults. All subjects re-
ceived buprenorphine and medical management and
were randomly assigned to receive either adjunctive
counseling or no additional treatment. The main end-
point was “successful outcome” defined by a number
of factors, including retention in treatment, self-reported opioid use, and the results of UDT. There
were two stages to the trial: the first stage included
four weeks of treatment with eight weeks of subse-
quent follow-up. Subjects who did not have successful
outcomes after the first stage then entered a second
stage including 16 additional weeks of treatment and
eight additional weeks of follow-up. Over the course
of both stages, there was no significant difference in
outcomes between patients assigned to adjunctive
counseling and those who were not. Only 6.6% of the
subjects were successful in the first stage. During the
second stage, 49% of subjects were successful while
receiving buprenorphine treatment, but only 8.6%
were able to maintain success in the eight weeks after
they were tapered off of buprenorphine.
Can outpatient buprenorphine treatment be effectively
delivered in a collaborative model of care?
Alford DP and colleagues [46].
To expand access to buprenorphine, there is a need for
more physicians to provide this treatment. Barriers in-
clude the demand on time and lack of ancillary support
[47,48]. A collaborative care model is one way to address
these barriers. Alford and colleagues [46] developed a
model in which physicians worked with nurses and other
clinical staff to provide office-based buprenorphine. In this
paper, they presented the one-year outcomes of 408 pa-
tients who were admitted to the program over a five-year
period. Success was defined as remaining in treatment for
12 months or tapering off of treatment after six months of
abstinence and treatment adherence. Overall, 51% of par-
ticipants were considered to be successful; 49% remained
in treatment, and 2% were successfully tapered. Another
6% transferred to methadone maintenance treatment, and
the remaining 42% were considered unsuccessful either by
dropping out of treatment (30%) or nonadherence despite
more intensive treatment (increased visits and more inten-
sive counseling) (12%). Older age, being employed, and
prior illicit buprenorphine use were associated with treat-
ment success.
Does integration of buprenorphine treatment with other
medical care improve access to treatment and health
outcomes?
Lucas GM and colleagues [49].
Another potential benefit of office-based buprenorphine
is the engagement of patients in medical care and improve-
ment in medical treatment outcomes. Lucas and colleagues
recruited 93 subjects from 2005 to 2009 and randomly
assigned them to buprenorphine treatment in an HIV
clinic or referral to community-based addiction treatment.
Subjects assigned to clinic-based buprenorphine were sig-
nificantly more likely to initiate buprenorphine treatment
within two weeks (84% versus 11%), to remain in treatment
Rastegar et al. Addiction Science & Clinical Practice 2013, 8:6 Page 7 of 10
http://www.ascpjournal.org/content/8/1/6for 12 months (74% versus 41%), and had a higher median
number of visits with their HIV provider (3.5 versus 3.0).
They were also less likely to have an opioid-positive UDT
(44% versus 65%) or cocaine-positive UDT (51% versus
66%). On the other hand, there were no significant dif-
ferences in months of antiretroviral treatment, baseline
CD4 cell count, HIV viral load, or proportion of pa-
tients with one or more emergency department visits
or hospitalizations.
Is extended-release naltrexone an effective treatment for
opioid dependence?
Krupitsky E and colleagues [50].
In 2010, the FDA approved extended-release injectable
naltrexone for the treatment of opioid dependence. This
approval was partly based on the results of a trial
conducted at 13 addiction treatment centers in Russia,
where opioid agonist treatment is prohibited. In this 24-
week trial, Krupitsky and colleagues randomly assigned
250 opioid-dependent subjects who had completed in-
patient detoxification to monthly injections of an
extended-release naltrexone (XR-NTX) or placebo. Sub-
jects assigned to XR-NTX were significantly more likely
to complete the trial (53% versus 38%) and were more
likely to be abstinent from opioids during weeks five
through 24 (36% versus 23%). There was also a signifi-
cantly greater reduction in opioid craving among those
subjects receiving XR-NTX.
Implications for practice
The availability of buprenorphine for office-based treat-
ment of opioid dependence has expanded its use. Weiss
and colleagues’ study [44] confirms the effectiveness of
this treatment but also shows that short-term treatment is
generally not effective. Their finding suggests that adjunct-
ive counseling offers little additional benefit, though it
should be noted that their subjects were largely employed,
well-educated, and had relatively brief histories of sub-
stance abuse; their findings may not apply to disadvan-
taged individuals or those with longer standing histories
of addiction. Alford and colleagues [46] offer a model that
may help expand treatment and include physicians who
would probably not be able to provide office-based
buprenorphine otherwise; in addition, this model is con-
sistent with the team-based care approach incorporated
into the medical home, an overall strategy to improve the
quality and patient-centeredness in primary care. Lucas
and colleagues [49] provide further evidence to support
the effectiveness of office-based buprenorphine treatment
and the integration of treatment with medical care. Al-
though they failed to find significant improvements in
clinical outcomes, other observational studies have found
a correlation between initiation of buprenorphine and
CD4 lymphocyte counts [51].Naltrexone is another option for the treatment of opi-
oid dependence, particularly for individuals in countries
or professions that do not permit agonist treatment.
However, its effectiveness is fairly modest and has never
been compared with full or partial agonist treatment.
Pharmacotherapy for alcohol dependence
Currently, there are three medications approved by the
US Food and Drug Administration for the treatment of
alcohol dependence: disulfiram, an aldehyde dehydro-
genase inhibitor approved in 1951; naltrexone, an opioid
antagonist approved in oral form in 1995 and in depot
form in 2006; and acamprosate, a GABA agonist/glutam-
ate antagonist approved in 2004. Other agents under in-
vestigation for the treatment of alcohol dependence
include two antiepileptics, topiramate and baclofen. Re-
cent literature investigating pharmacotherapies for alco-
hol dependence have focused on opioid antagonists,
acamprosate, topiramate, and baclofen.
Are opioid antagonists an effective treatment for alcohol
dependence?
Rösner S and colleagues [52].
Prior reviews and meta-analyses suggest a small-to-mod-
erate effect of opioid antagonists, mainly naltrexone, in
preventing relapse to heavy drinking among people with al-
cohol dependence. A prior systematic review [53], pub-
lished in 2005, included data from 29 studies and found
that short-term treatment with naltrexone decreased re-
lapse to alcohol use in 36% of subjects (number needed to
treat [NNT] = 7) and decreased return to heavy drinking in
13% (NNT= 12). These data were limited by short-term
treatment duration, small sample sizes, and lack of data on
psychosocial benefits of treatment. Rösner and colleagues
[52] updated this review, pooling data from 50 published
randomized controlled trials of opioid agonists that in-
cluded 7793 subjects. Primary outcomes were return to
any drinking, return to heavy drinking, and number of
drinking days. Most trials (N = 43) included data on
oral naltrexone, four focused on injectable extended-
release naltrexone, and three focused on nalmefene.
Follow-up ranged from four to 52 weeks. Oral naltrex-
one, compared with placebo, decreased return to any
drinking (71% versus 74%; relative risk [RR], 0.96; 95%
CI, 0.92-1.00), decreased return to heavy drinking (51%
versus 61%; RR 0.83; 95% CI, 0.76-0.90), and reduced
drinking days by four days per month (95% CI, 2.04-
5.75). Side effects were more common with naltrexone
than with placebo. Depot naltrexone and nalmefene
had similar efficacy to oral naltrexone.
Lee JD and colleagues [54].
This 12-week, open-label, single-arm, proof-of-concept
study explored the feasibility of implementing extended-
release naltrexone (380 mg monthly via intramuscular
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seling focusing on medication adherence and alcohol ab-
stinence) into primary care settings for the treatment of
alcohol dependence. A total of 72 subjects were enrolled in
the study; 65 received at least one injection, and 40 re-
ceived all three planned injections. By intent-to-treat ana-
lysis, median drinks per day decreased from 5.4 (95% CI,
4–7) to 3.4 (95% CI, 2–5). Among the 40 subjects receiving
all three injections, median drinks per day decreased from
4.1 (95% CI, 3–6) to 0.5 (95% CI, 0–1.7).
Is acamprosate effective for alcohol dependence?
Rösner S and colleagues [55].
Prior studies have suggested that acamprosate may
have some efficacy for maintaining abstinence in
alcohol-dependent patients; however, certain large ran-
domized trials have called its efficacy into question
[56-59]. In this systematic review, the authors reviewed
24 randomized clinical trials representing 6915 subjects
with alcohol dependence [55]. Treatment duration
ranged from eight weeks to one year; all studies coupled
medication with psychosocial treatments, and most
studies required a period of abstinence prior to initiating
study medication. Acamprosate increased self-reported
abstinence in 25% of patients compared with 17% in the
placebo group, with a relative risk of relapse to drinking
of 0.86 (95% CI, 0.81-0.91); it also increased cumulative
days abstinent by 11 days (95% CI, 5.1-16.8) but had no
effect on heavy drinking. Three studies compared
acamprosate with naltrexone and found no difference
between the two medications with respect to outcomes.
Are there non-FDA approved agents that are effective for
the treatment of alcohol dependence?
Paparrigopoulos T and colleagues [60].
Prior research suggests topiramate has efficacy for the
treatment of alcohol dependence [61-63]; however, those
studies focused on higher doses (150–300 mg daily),
which is also associated with a greater potential for side
effects. This open-label study [60] investigated the rate
of relapse to alcohol use among alcohol-dependent pa-
tients randomized to low-dose topiramate (≤75 mg daily)
(n = 30) or placebo (n = 60) after a period of inpatient
detoxification. After 16 weeks, relapse to alcohol use
was lower in the topiramate group (67%) compared with
placebo (86%), (HR 0.57, p = 0.014).
Garbutt JC and colleagues [64].
A small, open-label study of the GABA agonist baclo-
fen demonstrated reductions in drinks per drinking day
and number of drinking days, as well as an increase in
days abstinent, among people with alcohol dependence,
despite a relatively high dropout rate due to side effects
[65]. Additionally, baclofen has been evaluated as a po-
tential treatment option for alcohol-dependent patientswith cirrhosis given its lack of hepatotoxicity [66]. The
authors of this study investigated the efficacy of baclofen
compared with placebo for the treatment of alcohol de-
pendence in patients with or without cirrhosis (N = 80)
[64]. Seventy-six percent of patients completed the 12-
week study. The authors found no differences in per-
centage of heavy drinking days (roughly 26% in both
groups), time to first drink, time to relapse to heavy
drinking, or craving between the baclofen and placebo
groups.
Implications for practice
Opioid antagonists have efficacy for the treatment of al-
cohol dependence. Oral naltrexone is the most widely
studied agent in this medication class and reduces re-
lapse to alcohol use, relapse to heavy drinking, and heavy
drinking days. Extended release injectable naltrexone is
feasible to implement in primary care settings; however,
larger controlled trials investigating drinking outcomes
over time are warranted. Future investigations of opioid
antagonists for the treatment of alcohol dependence
should focus on comparisons with other medications
and treatment modalities and in various clinical settings.
Despite only moderate efficacy, acamprosate, in con-
junction with psychosocial treatments, should be consid-
ered a treatment option for alcohol dependence given
the limited pharmacotherapeutic options and serious-
ness of the disease process. Both low-dose topiramate
and baclofen may have a role in the treatment of alcohol
dependence based on these and prior studies. However,
larger randomized controlled trials are needed to ad-
equately assess their efficacy.
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